Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity

International Journal of Molecular Sciences

Miroslav Pohanka¹ 

[1] Faculty of Military Health Sciences, University of Defence, Trebesska 1575,Hradec Kralove CZ-50001, Czech Republic;

关键词: cholinergic anti-inflammatory pathway;    acetylcholinesterase;    butyrylcholinesterase;    Alzheimer disease;    neuroimmunity;    neuromodulation;   

DOI  :  10.3390/ijms15069809

来源: DOAJ

【 摘 要 】

Acetylcholinesterase (AChE) inhibitors are widely used for the symptomatic treatment of Alzheimer’s disease and other dementias. More recent use is for myasthenia gravis. Many of these inhibitors interact with the second known cholinesterase, butyrylcholinesterase (BChE). Further, evidence shows that acetylcholine plays a role in suppression of cytokine release through a “cholinergic anti-inflammatory pathway” which raises questions about the role of these inhibitors in the immune system. This review covers research and discussion of the role of the inhibitors in modulating the immune response using as examples the commonly available drugs, donepezil, galantamine, huperzine, neostigmine and pyridostigmine. Major attention is given to the cholinergicanti-inflammatory pathway, a well-described link between the central nervous system and terminal effector cells in the immune system.

【 授权许可】

Unknown